Conditions: Breast Cancer Infertility
Keywords: Letrozole IVF (in vitro fertilization) Cryopreservation Fertility Preservation Breast Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 41
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare two different ways to administer Letrozole to determine their effectiveness in blocking estrogen production during ovarian stimulation in patients with breast cancer prior to chemotherapy/radiotherapy so that oocytes or embryos can be cryopreserved and patients can possibly achieve a pregnancy after the treatment of breast cancer.

During standard ovulation stimulation, the estrogen levels will exceed normal levels and may reach 10 times the normal level for a 2 week period. This may not be desirable in breast cancer patients. The study hopes to determine if the investigators can stimulate oocyte development in the conventional way and administer different doses of Letrozole as the oocytes develop, to keep estradiol levels low, increase the number of oocytes the investigators are able to recover, and improve the quality of those oocytes.

Detailed description:
IVF is a process which involves a schedule of injectable medication to recruit several follicles, each containing an egg, to be retrieved under ultrasound guidance where they can be fertilized. Embryos are then selected to be transferred back into the patient's uterus or are cryopreserved and transferred at a later date.

Letrozole is a potent and highly selective third generation aromatase inhibitor that was developed in the early 1990's. Aromatase is an enzyme of the cytochrome P-450 superfamily and the product of the CYP19 gene, which catalyzes the reaction that converts androgenic substances to estrogens in many tissues, including the granulosa cells of ovarian follicles. Letrozole competitively inhibits the activity of the aromatase enzyme and has a half-life of approximately 48 hours. Because of its potent, sustained suppression in the plasma levels of estradiol, this drug has been recently found to be superior to tamoxifen in the treatment of advanced-stage post-menopausal breast cancer. Conventional ovarian stimulation often results in very high estrogen levels. Since the high estrogen levels are often unsafe for breast cancer patients, fixed dose aromatase inhibitor protocols with Letrozole were developed, to achieve effective ovarian stimulation with reduced estrogen levels to prevent tumor progression and short-term cancer recurrence.

A fixed dose of Letrozole has been used off-label as an ovulation induction agent in many centers to stimulate egg development for infertile couples and patients prior to undergoing chemotherapy for estrogen sensitive cancers.

The purpose of our study is to determine if titrated dose Letrozole in comparison to fixed dose Letrozole during gonadotropin stimulation in IVF in breast cancer patients results in lower estradiol levels and higher mature oocyte yield.

In patients who are scheduled to undergo treatment with IVF for fertility preservation due to breast cancer, we would like to prospectively randomize them to fixed dose vs. titrated dose of Letrozole. Due to time restraints for chemotherapy patients may present for ovarian stimulation prior to Day 2 of their menstrual cycle. If this were to occur, Ganirelix may be started to suppress the pituitary hormones for down regulation prior to starting stimulation medications until day 2 of menstrual bleeding. Eligible subjects will be fully informed about the nature of the trial. Subjects could be enrolled for IVF treatment at any point after breast cancer diagnosis following surgery but before the initiation of chemotherapy, if chemotherapy has been prescribed by their oncologist. After obtaining written informed consent, the subjects will be screened based on inclusion/exclusion criteria, medical and infertility history, Day 2/3 FSH and estradiol, physical and gynecological examination, oncology clearance and the Center's standard screening evaluations for IVF patients. A thorough gynecologic and endocrinologic evaluation will be performed before the start of any treatment. Laboratory assessments will include CBC, chemistry and lipid profile (see attached history and physical form). Vital signs including blood pressure, pulse, and weight will be assessed at baseline (prior to start of stimulation medication), with preoperative evaluation, on day of egg retrieval, and with post retrieval visits.

Patients will have serum blood tests for bHCG, FSH, AMH, Estradiol, and LH and vaginal sonogram on the second day of menstrual bleeding. Start of stimulation medication will proceed only with documentation of a serum negative pregnancy test. Patients will only be eligible to participate in the study for one cycle of in vitro fertilization.

Patients who elect to participate in the study will be provided with gonadotropin medications.

The starting dose of gonadotropins for both study groups would be determined by the patients' age and by antral follicle counts assessed by transvaginal ultrasound at the time of initial consultation. See below:

Age \<35 , Antral follicle Count \>15 gonadotropin dose 225 IU (150 IU FSH + 75 IU HMG; Age \<35, Antral follicle Count \<15 gonadotropin dose 300 IU (150 IU FSH + 150 IU HMG; Age 35-39, Antral follicle Count \>10 gonadotropin dose 300 IU (150 IU FSH + 150 IU HMG; Age 35-39, Antral follicle Count \<10 gonadotropin dose 450 IU (225 IU FSH + 225 IU HMG; Age\>40 Independent of antral follicle count, gonadotropin dose 450 IU (225 FSH + 225 IU HMG);

All patients would also be given a daily medication to prevent them from ovulating (Ganirelix), no later than cycle day #7 and continuing until HCG administration.

Group#1-Fixed Letrozole Group: Provided their blood tests and sonograms were within normal limits, patients who are randomized to fixed dose Letrozole will start Letrozole 5mg daily (orally) on the second day of their menstrual cycle and then gonadotropins on the fourth day of their menstrual cycle (Current Letrozole protocol at CRMI). Patients will be monitored with daily blood tests for estradiol and LH and sonogram every 1-3 days. Adjustments to gonadotropin dosing will be made as per usual protocol for IVF. Letrozole dose will not change and will continue for two weeks after egg retrieval.

Group #2-Titrated Letrozole Group: Provided their blood tests and sonograms were within normal limits, patients who are randomized to the titrated dose of Letrozole, will start gonadotropins in the evening of day #2 of their menstrual cycle with injectable follicle stimulating hormone (FSH) and human menopausal gonadotropin (HMG). Oral Letrozole will be added to the stimulation in the following titrated regimen:

Serum Estradiol level \<150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level \>350 pg/ml - 7.5 mg;

The maximal starting dose of Letrozole will be 5 mg, regardless of the initial estradiol level. The Letrozole dose may be reduced if the appropriate suppression of estradiol occurs. The maximal increase or decrease in Letrozole dose will be 2.5 mg/ day. Patients will be monitored with blood tests for estradiol and LH and sonograms starting on the second day of gonadotropin stimulation and every 1-3 days to monitor response and adjust medication dose as per our usual IVF protocol. Letrozole will be stopped for both groups on the day that HCG is given and resumed after egg retrieval. All patients will stay on the same dose of Letrozole that was required for their last day of ovarian stimulation for 2 weeks after stimulation to keep estradiol levels at a minimum. In addition, patients will have serum estradiol levels drawn weekly for 2 weeks after stimulation. Follow-up vital signs will be recorded along with CBC, liver function panel, and cholesterol panel 2 weeks after stimulation. They will also be asked to return 6 months to 1 year after completion of chemotherapy for AMH and FSH levels to evaluate ovarian reserve, and then followed on a yearly basis by phone/mail questionnaire or in person with an annual gynecological examination.

All study patients will be provided with an emergency 24-hour phone number to reach a physician to report adverse reactions to medications, and these physicians will file adverse event report forms to the principal investigator and data safety monitoring board. In addition, they will be asked to report any adverse reactions to medications during follicular monitoring sonograms. All decisions regarding daily medication doses will be determined by the study principal investigator. Otherwise, the treatment of ovarian stimulation, egg retrieval, and cryopreservation is identical to non-study patients undergoing ovarian stimulation, oocyte retrieval, and embryo/oocyte cryopreservation.

Two weeks after retrieval, follow-up instructions will be reviewed. Patients will be advised to refrain from embryo transfer for a minimum of 2 years after chemotherapy. Patients will not be permitted to undergo embryo transfer for a minimum of one year after completing chemotherapy and only after clearance for pregnancy has been obtained from their medical oncologist. Patients will be followed for five years on an annual basis with a follow-up telephone call from one of the investigators inquiring about health status (see patient follow-up data sheet). A pregnancy registry will be created for any pregnancy occurring following enrollment in the study. Detailed pregnancy outcome will be collected between age 2-5 years (see baby follow-up data sheet attached).

Arms:
arm 1: Patients who are randomized to the titrated dose of Letrozole, will start gonadotropins in the evening of day #2 of their menstrual cycle with injectable follicle stimulating hormone (FSH) and human menopausal gonadotropin (HMG). Oral Letrozole will be added to the stimulation in the following titrated regimen. arm 2: Patients who are randomized to fixed dose Letrozole will start Letrozole 5mg daily (orally) on the second day of their menstrual cycle and then gonadotropins on the fourth day of their menstrual cycle.

Interventions: intervention 1: Letrozole intervention 2: Letrozole
Intervention descriptions: intervention 1: Letrozole titrated regimen may be started on day 2 of menstrual cycle:

Serum Estradiol level \<150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level \>350 pg/ml - 7.5 mg; intervention 2: Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle

Protocol document:
Prot_SAP_000.pdf: 
Title: RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF  
NCT01035099 
Protocol ID: 0811010075 
 
WCM IRB-Approval and Amendment History 
 
Protocol Created 
11/04/2008 
Expedited Approval 
11/17/2009 
 
Amendment-001  
Expedited Approval 
07/14/2010 
 
  
Amendment-002  
Expedited Approval 
09/21/2015 
 
  
 
  
 
 
 
 
Study Design (for example, hypothesis, research question, standard and experimental procedures, 
special or unusual equipment of procedures): 
 
IVF is a process which involves a schedule of injectable medication to recruit several follicles,  each containing 
an egg, to be retrieved under ultrasound guidance where they can be fertilized. Embryos are then selected to 
be transferred back into the patient’s uterus or are cryopreserved and transferred at a later date. 
 
Letrozole is a potent and highly selective third generation aromatase inhibitor that was developed in the early 
1990’s. Aromatase is an enzyme of the cytochrome P-450 superfamily and the product of the CYP19 gene, 
which catalyzes the reaction that converts androgenic substances to estrogens in many tissues, including the 
granulosa cells of ovarian follicles. Letrozole competitively inhibits the activity of the aromatase enzyme and 
has a half-life of approximately 48 hours. Because of its potent, sustained suppression in the plasma levels of 
estradiol, this drug has been recently found to be superior to tamoxifen in the treatment of advanced-stage 
post-menopausal breast cancer. Conventional ovarian stimulation often results in very high estrogen levels. 
Since the high estrogen levels are often unsafe for breast cancer patients, fixed dose aromatase inhibitor 
protocols with Letrozole were developed, to achieve effective ovarian stimulation with reduced estrogen 
levels to prevent tumor progression and short-term cancer recurrence. 
 
 
A fixed dose of Letrozole has been used off-label as an ovulation induction agent in many centers to stimulate 
egg development for infertile couples and patients prior to undergoing chemotherapy for estrogen sensitive 
cancers. 
 
The purpose of our study is to determine if titrated dose Letrozole in comparison to fixed dose Letrozole 
during gonadotropin stimulation in IVF in breast cancer patients results in lower estradiol levels and higher 
mature oocyte yield. 
 
In patients who are scheduled to undergo treatment with IVF for fertility preservation due to breast cancer, we 
would like to prospectively randomize them to fixed dose vs. titrated dose of Letrozole. Due to time restraints 
for chemotherapy patients may present for ovarian stimulation prior to Day 2 of their menstrual cycle. If this 
were to occur, a gonadotropin-releasing hormone (GnRH) antagonist may be started to suppress the pituitary 
hormones for down regulation prior to starting stimulation medications. Eligible subjects will be  fully informed 
RESEARCH PLAN - RCT of Fixed vs Titrated Letrozole 


about the nature of the trial. Subjects could be enrolled for IVF treatment at any point after breast cancer 
diagnosis but before the initiation of chemotherapy, if chemotherapy has been prescribed by their oncologist. 
After obtaining written informed consent, the subjects will be screened based on inclusion/exclusion criteria, 
medical and infertility history, ovarian reserve (eg, antral follicle count, AMH, FSH) and estradiol, physical 
and gynecological examination, oncology clearance and the Center’s standard screening evaluations for IVF 
patients. A thorough gynecologic and endocrinologic evaluation will be performed before the start of any 
treatment. Laboratory assessments will include CBC, chemistry and lipid profile (see attached history and 
physical form). Vital signs including blood pressure, pulse, and weight will be assessed at baseline (prior to 
start of stimulation medication), with preoperative evaluation, on day of egg retrieval, and with post retrieval 
visits. 
 
Patients will have serum blood tests for bHCG, FSH, AMH, Estradiol, and LH and vaginal sonogram. Start of 


stimulation medication will proceed only with documentation of a serum negative pregnancy test. Patients will 
only be eligible to participate in the study for one cycle of in vitro fertilization. 
Patients who elect to participate in the study will be provided with gonadotropin medications. 
 
The starting dose of gonadotropins for both study groups would be determined by the patients' age and by 
antral follicle counts assessed by transvaginal ultrasound at the time of initial consultation. The HMG form of 
gonadotropin may be added to the FSH formulation, as needed. See below: 
Age <35 , Antral follicle Count >15 gonadotropin dose 150 - 225 IU 
Age <35, Antral follicle Count <15 gonadotropin dose 225 - 300 IU 
 
Age 
35-39, 
Antral 
follicle 
Count 
>10 
gonadotropin 
dose 
150 
- 
300 
IU 
Age 
35-39, 
Antral 
follicle 
Count 
<10 
gonadotropin 
dose 
300 
- 
450 
IU 
Age>40 Independent of antral follicle count, gonadotropin dose 300 - 450 IU. All patients would also be 
given a daily medication to prevent them from ovulating (GnRH e.g. Ganirelix, Cetrotide), no later than 
stimulation day #7 and continuing until HCG administration. 
 
Group#1-Fixed Letrozole Group: Provided their blood tests and sonograms were within normal limits, patients 
who are randomized to fixed dose Letrozole will start Letrozole 5mg daily (orally) and then gonadotropins 2 
days later (Current Letrozole protocol at CRM). Patients will be monitored with blood tests for estradiol and 
LH and sonogram every 1-3 days. Adjustments to gonadotropin dosing will be made as per usual protocol for 
IVF. Letrozole dose will not change and will continue for up to two weeks after egg retrieval. 
 
Group #2-Titrated Letrozole Group: Provided their blood tests and sonograms were within normal limits, 
patients who are randomized to the titrated dose of Letrozole, will start gonadotropins in the evening at the 
start of stimulation with injectable follicle stimulating hormone (FSH) and human menopausal gonadotropin 
(HMG). Oral Letrozole will be added to the stimulation in the following titrated regimen: 
 
Serum Estradiol level <150 pg/ml- No Letrozole 
Serum Estradiol Level 150-250 pg/ml- 2.5mg 
Serum Estradiol Level 251-350 pg/ml- 5  mg 
Serum Estradiol Level  >350 pg/ml - 7.5 mg 
 
The maximal starting dose of Letrozole will be 5 mg, regardless of the initial estradiol level. The Letrozole 
dose may be reduced if the appropriate suppression of estradiol occurs. The maximal increase or decrease in 
Letrozole dose will be 2.5 mg/ day. Patients will be monitored with blood tests for estradiol and LH and 
sonograms starting on the second day of gonadotropin stimulation and every 1-3 days to monitor response and 
adjust medication dose as per our usual IVF protocol. Letrozole will be stopped for both groups on the day 
that HCG is given and resumed after egg retrieval. All patients will stay on the same dose of Letrozole that 
was required for their last day of ovarian stimulation for up to 2 weeks after stimulation to keep estradiol 
levels at a minimum. In addition, patients will have serum estradiol levels drawn weekly for 2 weeks after 
stimulation. Follow-up vital signs will be recorded along with CBC, liver function panel, and cholesterol panel 
1-2 weeks after stimulation, if oncology treatment is not started immediately after retrieval. They will also be 
asked to return 6 months to 1 year after completion of chemotherapy for AMH and FSH levels to evaluate 
ovarian reserve, and then followed on a yearly basis by phone/mail questionnaire or in person with an annual 
gynecological examination. 
 
All study patients will be provided with an emergency 24-hour phone number to reach a physician to report 
adverse reactions to medications, and these physicians will file adverse event report forms to the principal 
investigator and data safety monitoring board. In addition, they will be asked to report any adverse reactions to 
medications during follicular monitoring sonograms. All decisions regarding daily medication doses will be 
determined by the study principal investigator. Otherwise, the treatment of ovarian stimulation, egg retrieval, 
and cryopreservation is identical to non-study patients undergoing ovarian stimulation, oocyte retrieval, and 
embryo/oocyte cryopreservation. 
 
After retrieval, follow-up instructions will be reviewed. Patients will be advised to refrain from embryo 
transfer for a minimum of 2 years after chemotherapy. Patients will not be permitted to undergo embryo 
transfer for a minimum of one year after completing chemotherapy and only after clearance for pregnancy has 


Gonadotropins 
Ganirelix 
Retrieval 
Ganirelix 
Letrozole 5 mg/d 
Gonadotropins 
been obtained from their medical oncologist. Patients will be followed for five years on an annual basis with a 
follow-up telephone call from one of the investigators inquiring about health status (see patient follow-up data 
sheet). A pregnancy registry will be created for any pregnancy occurring following enrollment in the study. 
Detailed pregnancy outcome will be collected between age 2-5 years (see baby follow-up data sheet attached). 
 
 
 
 
 
FIXED LETROZOLE PROTOCOL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cycle days 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 ……………. 
luteal phase menses 
 
 
 
 
 
 
TITRATED LETROZOLE PROTOCOL 
 
 
 
cycle days 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 ……………. 
luteal phase  menses 
Ganirelix 
ole sta 
2.5 -7.5
rting d 
mg/d (
ose 5 
dose ba
g/d 
on estradiol 
Ganirelix 
Retrieval 
Maximal Letro 
Letrozole titration 
m
Gonadotropins 


 
 
 
 
 
 
 
A2. Rationale and justification for the study (for example, historical background, investigator’s personal 
experience, 
pertinent medical literature): 
For several years in Europe and North America, aromatase inhibitors have been used to block estrogen 
production in the treatment of post-menopausal breast cancer. Researchers in the United States and Canada 
have used aromatase inhibitors in otherwise healthy women undergoing ovulation induction. By blocking 
estrogen production, many researchers have found that ovulation induction could be performed with 
significantly lower doses of fertility medications (Fertil Steril 75:305-9,2001; Fertil Steril 86(5):1428-1431; 
Fertil Steril 85:1774-7, 2006). Pregnancy outcome was similar to that of traditional stimulation protocols 
(Journal of the Society for Gynecologic Investigation 11(6):406-15,2004). 
 
In 2005, an observational pilot study investigated 147 low responder patients with previously cancelled IVF 
cycles. 71 patients were treated with 2.5 mg Letrozole and FSH and 76 patients were similarly treated 
without Letrozole. Antagonist was added in both groups during the first 5 days of stimulation. The Letrozole 
group had more oocytes retrieved and higher implantation rates (Fertil Steril :84(1):82-7, 2005). In 2006,  
Verpoest et al. published a small randomized prospective pilot study investigating the effects of adding 
aromatase inhibitors to ovarian stimulation for IVF or ICSI on endocrine parameters, endometrial thickness 
and pregnancy rates. They showed that median estradiol concentrations were significantly lower in the 
Letrozole group vs. no Letrozole, whereas endometrial thickness was significantly greater in the Letrozole 
group. 
 
In 2005, at our institution, a Letrozole protocol was applied to a population of women with breast cancer 
undergoing fertility preservation. 60 women with breast cancer, were prospectively followed after fertility 
preservation procedures with tamoxifen alone or in combination with low dose FSH, or Letrozole in 
combination with low dose FSH. After IVF, all resultant embryos were cryopreserved. The combination of 
low-dose FSH with tamoxifen or Letrozole resulted in higher embryo yield compared to tamoxifen alone. 
Recurrence rates did not seem to be increased. The Letrozole protocol resulted in lower peak estradiol levels. 
(J Clin Oncol 23:4347-4353, 2005). 
 
In 2006, at out institution, 47 breast cancer patients were studied who received 5mg/d Letrozole and 150-300 
IU FSH to cryopreserve embryos or oocytes. Age matched retrospective controls were selected from women 
who underwent IVF for tubal disease. Letrozole with FSH stimulation resulted in significantly lower peak 
estradiol levels and 44% reduction in gonadotropin requirement, compared to controls. Length of stimulation, 
number of embryos obtained, and fertilization rates were similar. The mean delay from surgery to 
cryopreservation without delay in chemotherapy was 39 days with 81% of patients completing their 
stimulation within the 8 weeks of surgery. (J Clin Endocrinol Metab 91:3885-3890, 2006) 
 
At our institution, 215 women with breast cancer were prospectively evaluated for fertility preservation 
before adjuvant chemotherapy. Of those 79, elected to undergo controlled ovarian hyperstimulation with 
letrozole 5 mg x 5 days and gonadotropins for embryo and oocyte cryopreservation. The remaining 136 
patients underwent no fertility-preservation procedures and served as controls. In the fertility preservation 
group the mean E2 was 406 ± 257 pg/ml. The hazard rate for recurrence and the survival rate after IVF was 
not compromised in comparison to the control group after 23 months. (J Clin Onc 26:2630-2635, 2008) 
 
References: 
 
1. Al-Fozan H, Al-Khadouri M, Tan SL, Tulandi T. A randomized trial of Letrozole versus clomiphene 
citrate in women undergoing superovulation. Fertil Steril. 2004 Dec;82(6):1561-3. 


 
2. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with 
letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008 
Jun 1;26(16):2630-5. 
 
3. Barroso G, Menocal G, Felix H, Rojas-Ruiz JC, Arslan M, Oehninger S. Comparison of the efficacy of the 
aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone 
in controlled ovarian hyperstimulation: a prospective, randomized, blinded clinical trial. Fertil Steril.        
2006 Nov;86(5):1428-31. 
 
4. Dixon JM, Love CDB, Bellamy COC, Cameron DA, Leonard RCF, Smith H, Miller WR. Letrozole as 
primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer research and 
Treatment. 2001; 66:191-199. 
 
5. Garcia-Velasco JA, Moreno L, Pacheco A, Guillén A, Duque L, Requena A, Pellicer A. The aromatase 
inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization 
outcome in low responder patients: a pilot study. Fertil Steril. 2005 Jul;84(1):82-7. 
 
6. Jee BC, Ku SY, Suh CS, Kim KC, Lee WD, Kim SH. Use of letrozole versus clomiphene citrate combined 
with gonadotropins in intrauterine insemination cycles: a pilot study. Fertil Steril. 2006 Jun;85(6):1774-7. 
 
7. Mitwally MF, Casper RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled 
ovarian hyperstimulation. J Soc Gynecol Investig. 2004 Sep;11(6):406-15. 
 
8. Mitwally MF, Casper RF. Single-dose administration of an aromatase inhibitor for ovarian stimulation. 
Fertil Steril. 2005 Jan;83(1):229-31. 
 
9. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an 
inadequate response to clomiphene citrate. Fertil Steril. 2001 Feb;75(2):305-9. 
 
10. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: A 
prospective controlled comparison of ovarian stimulation with Tamoxifen and Letrozole for embryo 
cryopreservation. Journal of Clinical Oncology. 2005 July; 23(19): 4347-53. 
 
11. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, Bang H. Letrozole reduces estrogen and 
gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J 
Clin Endocrinol Metab. 2006 Oct;91(10):3885-90. 
 
12. Verpoest WM, Kolibianakis E, Papanikolaou E, Smitz J, Van Steirteghem A, Devroey P. Aromatase 
inhibitors in ovarian stimulation for IVF/ICSI: a pilot study. Reprod Biomed Online. 2006 Aug;13(2):166-72. 
 
 
 
 
 
 
 
 
 
A3. Primary study endpoint: 


Mature oocyte yield 
 
 
 
 
 
 
A4. Primary objective: 
The purpose of our study is to determine if titrated dose Letrozole in comparison to fixed dose Letrozole 
during gonadotropin stimulation in IVF in breast cancer patients results in 50% increased mature oocyte yield 
 
 
 
A5. Secondary objectives: 
Peak Serum Estradiol Level (pg/ml) 
FSH ng/ml on Cycle Day 2 
AMH ng/ml on Cycle Day 2 
Antral follicle count on Cycle Day 2 
Total days of stimulation medications 
Total medication dose 
Adverse events from medications 
Total number of oocytes 
Number of mature oocytes  
Number of follicles on day of HCG 
Number of fertilized (2PN) oocytes (if applicable) 
Number of good quality embryos (if applicable) 
Cycle cancellation rate 
1 year follow-up breast cancer recurrence rate 
2 year follow-up breast cancer recurrence rate 
5 year follow-up breast cancer recurrence rate 
 
 
A6. Inclusion/Exclusion criteria: 
Inclusion Criteria: 
Female breast cancer patient with breast cancer diagnosis undergoing chemotherapy desiring fertility 
preservation with oocyte or embryo cryopreservation 
Healthy subject according to documented medical history and physical examination who has been 
diagnosed with breast cancer (estrogen and progesterone receptor positive and/or negative) 
Age less that 45 years at time of informed consent 
Verbal or written clearance from medical or surgical oncologist to undergo controlled ovarian 
hyperstimulation-IVF. 
Delay to surgery or chemotherapy treatment will not jeopardize cancer treatment outcome 
Ovarian stimulation will not affect cancer treatment plan 
Transvaginal ultrasound scan (US) within one month of starting stimulation with no clinically significant 
pelvic mass 
Serum FSH level (Day 2-4) less than 25, since our center has documented pregnancies with FSH up to 
27miu/ml 
Negative pregnancy test prior to beginning Letrozole or gonadotropin therapy 
Willing and able to comply with the protocol 
Voluntary provision of written informed consent, prior to any study-related procedure that was not part of 


normal medical care, with the understanding that the subject can withdraw consent at any time without 
prejudice to her future medical care 
Willingness to provide follow-up information on herself and babies born as part of this study 
 
Exclusion Criteria: 
Patients not medically cleared by their oncologist 
 
Patients with stage IV breast cancer based on the poor prognosis, general health of the patient, and higher 
uncertainty with delaying chemotherapy 
 
Any clinically relevant abnormal laboratory value (FSH >25 miu/ml, renal function, (greater than two 
times normal value), hepatic function (greater than two times normal value), blood biochemistry, 
hematology (elevated white blood count greater than 1.5 times the normal value, hemoglobin <10mg/dL, 
thrombocytopenia), abnormal cholesterol profile (total cholesterol ≥ 300mg/dL, abnormal LDL greater 
than 2 times normal value,) based on a fasting sample during the screening phase 
 
Contraindications for the use of gonadotropins (i.e. Tumors other than breast cancer, pregnancy, lactation, 
undiagnosed vaginal bleeding) 
 
Recent or current medical conditions where the patient is not medically stable to undergo stimulation or 
egg retrieval, HIV infection, diabetes, cardiovascular disease, gastrointestinal, hepatic disease, 
undiagnosed pelvic mass, renal or pulmonary disease 
 
History or presence of alcohol or drug abuse within 12 months of signing consent 
 
History of severe allergic or anaphylactic reactions or hypersensitivity to any of the concomitant 
medication prescribed as part of the treatment regimen in this protocol 
 
Administration of investigational drugs within three months prior to signing the informed consent 
Use of insulin sensitizing agents at least one month prior to signing informed consent 
Any patient who is not a candidate for IVF 
 
 
 
 
 
 
 
A7. Treatment plan: (include amount and frequency of samples of blood and other bodily fluids in 
chart below) 
 
Bodily Fluid 
Amount 
Frequency 
Total 
Blood 
5cc 
12-14 
60-70cc 
Urine 
20cc 
1 
20 cc 
Other  
 
 
 
A8. Statistical considerations (e.g. justification for sample size or “n”): 


Sample size: 
The primary aim of the study is to determine if titrated dose Letrozole in comparison to fixed dose Letrozole 
during gonadotropin stimulation in IVF in breast cancer patients results in a 50% increased mature oocyte yield. 
With a sample size of 25 patients per group, the study will have 80% power (alpha=0.05) to detect a difference in 
the mean number of mature oocytes of 4.3 between the titrated dose group and the fixed dose group. This is 
based on an expected mature oocyte yield of 8.7±4.8 in the fixed dose group and an expected 50% increase in the 
mature oocyte yield in the titrated dose group (e.g., [(13.0-8.7)/8.7 = 50% increase]). 
 
Analysis Plan: 
The mean and median mature oocyte yield will initially be compared between the titrated and fixed dose groups 
by the two-group t-test and Wilcoxon rank-sum test, respectively, in an intent-to-treat analysis.  Stratification by 
age group at the time of randomization will be taken into account by performing analysis of covariance 
(ANCOVA) for the primary endpoint (i.e., ooctye yield), using the stratification factor (age group) as a covariate 
in the ANCOVA model (in addition to the dose group variable) (this will also be an intent-to-treat analysis). The 
ANCOVA procedure recognizes the reduction in variability in the titrated-versus-fixed dose comparison that is 
attained by use of stratification (by age group) at the time of randomization. This reduction in variability will 
increase the power of the study (>80%) to detect the hypothesized difference and will potentially allow for the 
detection of smaller differences with the stated sample size of 50 patients. 
 
Secondary continuous endpoints will initially be compared by the t-test or Wilcoxon rank-sum test, as 
appropriate, and secondary categorical endpoints will be compared by the chi-square test or Fisher’s exact test, as 
appropriate.  Similarly, to account for stratification at randomization, ANCOVA and multivariate logistic 
regression will be performed for the secondary endpoints, as appropriate, by using age group as a covariate in the 
multivariate models. One-year and 2-year recurrence-free survival will be preliminary assessed by the Kaplan- 
Meier method and the log-rank test will be employed for comparing recurrence-free survival between the titrated 
and fixed dose groups. 
 
Subjects who discontinue the study prior to egg retrieval will be still be considered in the primary intent-to-treat 
analysis by assigning a value of zero eggs retrieved for the primary endpoint (i.e., oocyte yield).  This will 
conservatively underestimate any observed titrated-versus-fixed dose effect but will preserve the benefit of 
randomization. A secondary analysis will be performed to assess the between dose group effect after these 
patients have been removed, but this will only be for descriptive purposes. 
 
All p-values will be two-sided with statistical significance evaluated at the 0.05 alpha level and 95% confidence 
intervals will be calculated to assess the precision of the obtained estimates. All analyses will be performed in 
SAS Version 9.1 (SAS Institute, Inc., Cary, NC). 
 
Randomization: 
A series of randomized blocks of four will be generated for the study. This will provide assurance that after four 
patients are enrolled, there will be two patients assigned to the titrated dose letrozole group and two patients 
assigned to the fixed dose letrozole group. The blocked randomization will be stratified according to age group: 
≤32 years, 33-36 years, and ≥37 years. This process of blocked randomization and stratification ensures an equal 
distribution between the two study arms of patients in the specified age groups. The study research coordinator 
will have access to the computer generated randomization file and will make assignments accordingly. 
 
 
 
 
A9. Relative importance/value of the trial, considering “standard” therapy and published/competing 
trials. Please 
specify what the current standard of care is. 
This trial will investigate if a superior and safer controlled ovarian hyperstimulation protocol with Letrozole 
exists for breast cancer patients for fertility preservation and cryopreservation of oocytes or embryos. As 
these patients cannot delay chemotherapy, any improvement in oocyte yield would be a significant benefit. 


WCM IRB-approved approval and amendments History 
 
Protocol Created 
11/04/2008 
Expedited Approval 
11/17/2009 
 
 
Amendment-001  
Expedited Approval 
07/14/2010 
 
  
Amendment-002  
Expedited Approval 
09/21/2015 
 
  
Renewal-001  
Expedited Approval 
01/26/2010 
 
  
Renewal-002  
Approved 
01/12/2011 
 
  
Renewal-003  
Approved 
01/17/2012 
 
  
Renewal-004  
Expedited Approval 
02/01/2013 
  
Renewal-005  
Expedited Approval 
01/24/2014 
  
Renewal-006  
Approved 
12/17/2014 
  
Renewal-007  
Approved 
12/03/2015 
 
  
Renewal-008  
Approved 
06/22/2017 
  
Renewal-009  
Expedited Approval 
07/20/2018